11 active not recruiting. 11 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 11 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Refractory Osteosarcoma: new trials by email Literature Review of Refractory Osteosarcoma trials Research Report on Refractory Osteosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma Durvalumab, Oleclumab - Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 75 | 2020-11-26 | 2026-11-03 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma Docetaxel, Gemcitabine, Hydroxychloroquine - Recurrent Osteosarcoma, Refractory Osteosarcoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 31 | 2019-01-28 | 2026-05-14 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2018-04-27 | 2026-05-22 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-28 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-06-17 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
Osteosarcoma (11) · Sarcoma (9) · Hepatoblastoma (8) · Rhabdomyosarcoma (8) · Wilms Tumor (8) · Ependymoma (7) · Glioma (7) · Histiocytosis, Langerhans-Cell (7) · Lymphoma, Non-Hodgkin (7) · Medulloblastoma (7) · Neuroblastoma (7) · Neuroectodermal Tumors, Primitive, Peripheral (7) · Rhabdoid Tumor (7) · Sarcoma, Ewing (6) · Central Nervous System Neoplasms (4)
Neoplasms (11) · Neoplasms by Histologic Type (11) · Neoplasms, Bone Tissue (11) · Neoplasms, Connective Tissue (11) · Neoplasms, Connective and Soft Tissue (11) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Genetic Diseases, Inborn (8) · Kidney Diseases (8) · Kidney Neoplasms (8)
Magnetic Resonance Spectroscopy (4) · Nuclear Medicine Department, Hospital (4) · Phantoms, Imaging (4) · X-Rays (4) · Biopsy (3) · Specimen Handling (3) · ensartinib (2) · ivosidenib (2) · larotrectinib (2) · selpercatinib (2) · tipifarnib (2) · ulixertinib (2) · CTLA-4 Antigen (1) · Cyclophosphamide (1) · Disulfides (1)
National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (3)
United States (11) · Puerto Rico (7) · Australia (4) · Canada (2)
Amir A Jazaeri (1) · Andrea T Franson (1) · Christine A Pratilas (1) · Donald W Parsons (1) · Elizabeth D Alva (1) · John A Livingston (1) · Katherine A Janeway (1) · Kieuhoa T Vo (1) · Meredith S Irwin (1) · Neeta Somaiah (1) · Srivandana Akshintala (1)
PMID 31401903, PMID 33591402, PMID 34486544, PMID 35353553, PMID 38935895, PMID 41166674, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (8), P30CA016672 (1)